UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
FORM
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
_______________________________
(Exact name of registrant as specified in its charter) |
_______________________________
Alberta, |
|
| N/A | |
(State or Other Jurisdiction of Incorporation) |
| (Commission File Number) |
| (I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices) (Zip Code)
(
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
_______________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
|
| OTCQB |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On March 4, 2025, Zomedica Corp. (the “Company”) was notified by The NYSE American LLC (“NYSE American”) that as a result of the Company’s previously disclosed noncompliance with Section 1003(f)(v) of the NYSE American Company Guide whereby the Company’s common shares were trading for a substantial period of time at a low price per share, NYSE American has suspended trading in the Company’s common shares as of March 4, 2025. NYSE American further indicated that it will apply to the Securities and Exchange Commission (the “SEC”) to delist the Company’s common shares upon completion of all applicable procedures.
The Company had applied to have its common shares quoted on the OTC Markets’ OTCQB® market tier, an electronic quotation service operated by OTC Markets Group Inc. for eligible securities traded over-the-counter. The Company received its approval recently and expects that trading of the Company’s common shares will commence on the OTCQB Market at the open of business on March 5, 2025 under trading symbol ZOMDF.
The transition to the quotation of the Company’s common shares on the OTCQB Market will have no effect on the Company’s business or operations. The Company will continue to file periodic and other required reports with the SEC under applicable federal securities laws that will be available on the SEC’s website, www.SEC.gov.
A press release announcing the events described in this Item 3.01 is furnished here as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(d) | Exhibit No. |
| Description |
|
|
|
|
|
| ||
| 104 |
| Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| 2 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ZOMEDICA CORP. |
| |
|
|
|
|
Date: March 4, 2025 | By: | /s/Karen DeHaan-Fullerton |
|
| Name: | Karen DeHaan-Fullerton |
|
| Title: | General Counsel and Corporate Secretary |
|
| 3 |
EXHIBIT INDEX
(d) | Exhibit No. |
| Description |
|
|
|
|
|
| ||
| 104 |
| Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| 4 |
EXHIBIT 99.1
FOR IMMEDIATE RELEASE
Zomedica Corp. Announces Transition to OTCQB Market
Zomedica’s ticker symbol will change to ZOMDF
ANN ARBOR, MI / ACCESS Newswire / March 4, 2025 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a leading veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced that its common shares will be delisted from the NYSE American exchange, due to their determination that the Company is no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the common shares.
Zomedica expects its shares to begin trading on the OTCQB Venture Market under the ticker symbol “ZOMDF”, effective March 5, 2025
"While we are disappointed by the delisting of our common shares from NYSE American, this transition to the OTCQB Market continues to allow Zomedica to maintain its strong engagement with investors while allowing us to focus our resources on driving growth and advancing our pipeline of veterinary products," said Larry Heaton, Chief Executive Officer of Zomedica. "While our common shares will be trading on OTCQB, the value of the company’s assets, and our opportunities for growth remain the same. We remain dedicated to delivering value to our shareholders and the veterinary community as we continue to innovate in the animal health sector.”
The company will continue to file periodic reports with the U.S. Securities and Exchange Commission (SEC) and comply with applicable regulatory requirements.
Shareholders and investors will continue to have access to real-time trading data, news, and financial disclosures through the OTC Markets website (www.otcmarkets.com) and Zomedica’s investor relations page.
About Zomedica Corp.
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW™ digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit www.zomedica.com.
| 1 |
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the anticipated transition to the OTCQB Market and the company’s business outlook. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially. Factors that may impact future results include, but are not limited to, market conditions, regulatory approvals, and competitive developments. Zomedica disclaims any obligation to update or revise forward-looking statements except as required by law.
Investor & Media Contact:
Investor Relations
(734) 369-2555 extension #5
| 2 |